Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For malignant growth, solid cancers must stimulate the formation of new blood vessels by producing vascular endothelial growth factor (VEGF-A), which is required for the survival of tumor-associated vessels. Novel anticancer agents that block VEGF-A signaling trigger endothelial cell (EC) apoptosis and vascular regression preferentially within tumors, but how the ECs die is not understood. In this study, we demonstrate that VEGF-A deprivation, provoked either by drug-induced tumor shrinkage or direct VEGF-A blockade, up-regulates the proapoptotic BH3 (Bcl-2 homology 3)-only Bcl-2 family member Bim in ECs. Importantly, the tumor growth inhibitory activity of a VEGF-A antagonist required Bim-induced apoptosis of ECs. These findings thus reveal the mechanism by which VEGF-A blockade induces EC apoptosis and impairs tumor growth. They also indicate that drugs mimicking BH3-only proteins may be exploited to kill tumor cells not only directly but also indirectly by ablating the tumor vasculature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BIM polymorphisms that decrease BIM expression are well known to cause patient resistance to many conventional cancer treatments including anti-VEGF [26–28].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679 · cited 4×
“Because the prosurvival protein Bcl-2 is up-regulated in ECs after stimulation with VEGF (Gerber et al., 1998), we reasoned that a proapoptotic BH3 (Bcl-2 homology 3)-only member of that family (Youle and Strasser, 2008) might initiate the EC death provoked by falling VEGF levels when solid tumors…”
BackgroundInfluentialSelf-citationTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Because the prosurvival protein Bcl-2 is up-regulated in ECs after stimulation with VEGF (Gerber et al., 1998), we reasoned that a proapoptotic BH3 (Bcl-2 homology 3)-only member of that family (Youle and Strasser, 2008) might initiate the EC death provoked by falling VEGF levels when solid tumors…”
BackgroundVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954 · Cited by 1,631
Bouillet, P., Metcalf, D., Huang, D. C. S., Tarlinton, D. M., Kay, T. W. H., Köntgen, F., Adams, J. M., & Strasser, A. (1999) · Science · doi:10.1126/science.286.5445.1735 · Cited by 1,504 · cited 6×
“The BH3-only protein Bim (O’Connor et al., 1998) is critical for the apoptosis induced by cytokine deprivation in several cell types (Bouillet et al., 1999; Youle and Strasser, 2008), and notably, in early development of the eye, Bim is critical for the programmed cell death of the ECs comprising…”
BackgroundMethodInfluentialSelf-citationp53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Self-citationBim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166
Self-citationGerber, H.-P., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 981 · cited 2×
“Because the prosurvival protein Bcl-2 is up-regulated in ECs after stimulation with VEGF (Gerber et al., 1998), we reasoned that a proapoptotic BH3 (Bcl-2 homology 3)-only member of that family (Youle and Strasser, 2008) might initiate the EC death provoked by falling VEGF levels when solid tumors…”
Background
Cited by
The BCL-2 protein family, BH3-mimetics and cancer therapy
Delbridge, A. R. D., & Strasser, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.50 · Cited by 531
Self-citationDeciphering the rules of programmed cell death to improve therapy of cancer and other diseases
Strasser, A., Cory, S., & Adams, J. M. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.307 · Cited by 532
Self-citationPutoczki, T. L., Thiem, S., Loving, A., Busuttil, R. A., Wilson, N. J., Ziegler, P. K., Nguyen, P. M., Preaudet, A., Farid, R., Edwards, K. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.017 · Cited by 421
“Incidentally, inhibition of IL-11 signaling increased expression of the pro-apoptotic protein BIM in a manner akin to that observed in response to therapeutic inhibition of the STAT3-target VEGF-A (Naik et al., 2011).”
Endothelial cell apoptosis in angiogenesis and vessel regression
Watson, E. L., Grant, Z. L., & Coultas, L. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2577-y · Cited by 153
“The importance of apoptosis to vessel regression in these cases is supported by studies showing that hyaloid regression [19–22], retinal vaso-obliteration [19], and the tumor growth-suppressing effects of VEGF-A neutralization [23] are all inhibited in mice lacking genes essential for apoptosis.”
Self-citationTumor Angiogenesis and Anti-angiogenic Therapy
Kubota, Y. (2012) · The Keio Journal of Medicine · doi:10.2302/kjm.61.47 · Cited by 128
Chen, C., Du, W., Rao, S., Tan, Y., Hu, X., Luo, M., Ou, Q., Wu, P., Qing, L., Cao, Z., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.05.020 · Cited by 76
Watson, E. C., Koenig, M. N., Grant, Z. L., Whitehead, L., Trounson, E., Dewson, G., & Coultas, L. (2016) · Development · doi:10.1242/dev.137513 · Cited by 53
“The intrinsic apoptosis pathway is essential for survival regulation in ECs: loss of the BH3-only protein BIM prevents EC apoptosis during normal and tumour-associated angiogenesis in vivo (Koenig et al., 2014; Naik et al., 2011; Wang et al., 2011), whereas EC-specific loss of the pro-survival BCL2 family protein MCL1…”
BackgroundSelf-citationThe Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA
Sun, J., Sun, Q., Brown, M. F., Dudgeon, C., Chandler, J., Xu, X. M., Shu, Y., Zhang, L., & Yu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043158 · Cited by 52
“Earlier work demonstrated the involvement of Bim and STAT3 during sunitinib-induced apoptosis in other cells types [38,39,40].”
BackgroundYu, J. H., Zhu, B., Riedlinger, G., Kang, K., & Hennighausen, L. G. (2012) · Hepatology · doi:10.1002/hep.25900 · Cited by 50
“In addition, BIM was also required for tumor cell apoptosis induced by a vascular endothelial growth factor A antagonist.(29) Roles for BIM and PUMA in suppressing oncogenesis have been described for B cell leukemias(30) and intestinal cells,(31,32) respectively.”
Badmann, A., Langsch, S., Keogh, A., Brunner, T., Kaufmann, T., & Corazza, N. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.185 · Cited by 40
Chu, Y., Li, H., Tan, H. S., Koh, V. C. Y., Lai, J. C. H., Phyo, W. M., Choudhury, Y., Kanesvaran, R., Chau, N. M., Toh, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134102 · Cited by 33
“demonstrated that destruction of tumor vasculature by VEGF-blocking antibodies was BIM-dependent [29] and Yang et al.”
BackgroundEndothelial cell survival during angiogenesis requires the pro-survival protein MCL1
Watson, E. L., Whitehead, L. W., Adams, R. H., Dewson, G., & Coultas, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.20 · Cited by 33
“(VEGF-A) inhibition can cause EC apoptosis in the case of tumor angiogenesis.(6) Despite the susceptibility of angiogenic”
BackgroundSelf-citationA miRNA-101-3p/Bim axis as a determinant of serum deprivation-induced endothelial cell apoptosis
Kim, J.-H., Lee, D.-K., Kim, J., Choi, S., Park, W., Ha, K., Kim, T. H., Choe, J., Won, M., Kwon, Y., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.219 · Cited by 33
“Indeed, inhibiting VEGF activity induces endothelial cell apoptosis by increasing Bim expression and vice versa.(44) In this study, we demonstrated that serum deprivation increased Bim expression via the downregulated biogenesis of miR-101-3p that targets the 3′-UTR of Bim mRNA, resulting in the increases in Bax activ…”
BackgroundKoenig, M. N., Naik, E., Rohrbeck, L., Herold, M. J., Trounson, E., Bouillet, P., Thomas, T., Voss, A. K., Strasser, A., & Coultas, L. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.90 · Cited by 30
“death and to date is the only BH3-only protein demonstrated to be necessary for this process.(9,17) VEGF-A has a key role in suppressing the activity of BIM: BIM is required for the apoptotic death of retinal endothelial cells during OIR,(17) a process suppressed by ectopic VEGF-A,(11) and BIM is required for the apop…”
BackgroundInfluentialSelf-citationContribution of cell death signaling to blood vessel formation
Tisch, N., & de Almodóvar, C. R. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03738-x · Cited by 27
“In this context, the BH3 only protein BIM is an essential inducer of apoptosis in ECs and normally suppressed by VEGF signaling [79, 80].”
BackgroundWang, S., Zaitoun, I. S., Johnson, R. P., Jamali, N., Gürel, Z., Wintheiser, C. M., Strasser, A., Lindner, V., Sheibani, N., & Sorenson, C. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178198 · Cited by 26
Self-citationBlocking endothelial apoptosis revascularizes the retina in a model of ischemic retinopathy
Grant, Z. L., Whitehead, L. W., Wong, V. H. Y., He, Z., Yan, R. Y., Miles, A. R., Benest, A. V., Bates, D. O., Prahst, C., Bentley, K., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci127668 · Cited by 25
“VEGFA promotes EC survival via the BCL2 pathway (33, 34).”
BackgroundSelf-citationGalán‐Moya, E. M., Treps, L., Oliver, L., Chneiweiss, H., Vallette, F. M., Bidère, N., & Gavard, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093505 · Cited by 25
Reg Gene Expression in Periosteum after Fracture and Its In Vitro Induction Triggered by IL-6
Tohma, Y., Dohi, Y., Shobatake, R., Uchiyama, T., Takeda, M., Takasawa, S., Tanaka, Y., & Ohgushi, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112257 · Cited by 19
“Bim is also required for the apoptotic death of tumor endothelial cells and for inhibition of tumor growth by VEGF neutralization [50].”
BackgroundModulation of Tumor Tolerance in Primary Central Nervous System Malignancies
Johnson, T. S., Munn, D. H., & Maria, B. L. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/937253 · Cited by 15
“Despite the strong rationale behind developing antiangiogenic drug candidates [138], agents such as bevacizumab, a humanized monoclonal antibody that targets VEGF, have yielded mixed results [3, 146, 147].”
So, E. C., Sallin, M. A., Zhang, X., Chan, S. L., Sahni, L., Schulze, D. H., Dávila, E., Strome, S. E., & Jain, A. K. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.05.001 · Cited by 17
Romeo, M. A., Montani, M. S. G., Benedetti, R., Arena, A., D’Orazi, G., & Cirone, M. (2021) · Biomolecules · doi:10.3390/biom11030344 · Cited by 14
“These cytokines may, in turn, increase ROS production in a positive regulatory circuit that amplifies pro-tumorigenic inflammation [37,38].”
BackgroundBreast Carcinoma Progression and Tumour Vascular Markers Related to Apoptotic Mechanisms
Rabajdová, M., Urban, P., Gregova, K., Varga, J., Fialkovicová, V., Kružliak, P., & Mareková, M. (2014) · Disease Markers · doi:10.1155/2014/156034 · Cited by 12
“VEGF may prevent EC apoptosis through various mediators including Bcl-2, A1, inhibition of apoptosis (IAP), and the PI3-kinase/Akt [17], MAPK/Erk and SAPK/JNK 9 [16], and signal transduction pathways.”
Halford, M. M., Tebbutt, N. C., Desai, J., Achen, M. G., & Stacker, S. A. (2012) · Colorectal Cancer · doi:10.2217/crc.12.9 · Cited by 8
Sorenson, C. M., Gurel, Z., Song, Y.-S., Peterson, K. D., Blodi, B. A., & Sheibani, N. (2024) · PLOS ONE · doi:10.1371/journal.pone.0297135 · Cited by 5
Bim regulation miRrors microRNA 17∼92 cluster expression in endothelial cells in vivo
Meng, X. W., & Kaufmann, S. H. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.127 · Cited by 3
Sheibani, N., Song, Y., Farnoodian, M., Inampudi, S., Hanna, B. A., Wang, S., Darjatmoko, S. R., & Sorenson, C. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910254 · Cited by 2
“These studies highlight the role played by BIM during the therapeutic removal of cells contributing to disease pathogenesis, most notably lung cancer and leukemias [6,11,12].”
BackgroundInfluential[Effect and significance of BH3-only protein in targeted therapy of non-small cell lung cancer].
Gao, W., Huang, W., & Liu, K. (2014) · PubMed Central · doi:10.3779/j.issn.1009-3419.2014.11.08 · Cited by 3
Naik, E., O’Reilly, L. A., Asselin-Labat, M.-L., Mérino, D., Lin, A. E.-J., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A. (2011) · The Journal of Cell Biology · doi:10.1083/jcb1935oia14 · Cited by 1
Self-citationKretzschmann, V. K. (2013) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.16431
Ferroptosis governs lymphatic vessel growth and regressionPreprint
Drekolia, M.-K., Wang, D., Chen, Y., Du, Y., Wittig, J., Xu, R., Schilling, D., Aliraj, B., Mettner, J., Gupta, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.18.689033 · Cited by 1
Metadata
- Authors
- Naik, E., O'Reilly, L. A., Asselin-Labat, M.-L., Merino, D., Lin, A., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A.
- Affiliations
- The University of Melbourne (AU)
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria 3052, Australia 1
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Strasser, Andreas
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2011-06-06
- Volume
- 208
- Issue
- 7
- Pages
- 1351-1358
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3135358
- OpenAlex
- W2163882639
- Cited by
- 31
- References
- 29
- Citations by year
- 2025: 1 · 2024: 2 · 2021: 2 · 2020: 2 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 6
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Leukemia and Lymphoma Society
- National Institutes of Health
- Genentech
- Medical Research Council (461221)
- National Health and Medical Research Council (461221, 516703, 461299)
- National Cancer Institute (R01CA043540, CA 43540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- building information modeling, endothelial cell apoptosis, tumor vasculature, tumor growth inhibition, BH3-only proteins, Bcl-2 family proteins, tumor angiogenesis, vascular regression, anticancer agents
- MeSH terms
- Bcl-2-Like Protein 11, Animals, Antineoplastic Agents, Melanoma, Experimental, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Proto-Oncogene Proteins, Recombinant Proteins, Thymidine Kinase, Ganciclovir, Gene Expression, Apoptosis, Mice, Knockout, Carcinoma, Lewis Lung, Vascular Endothelial Growth Factor A, Endothelial Cells, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.